VTRS Viatris Inc.
$18.72▲ +2.35%
Healthcare
Other
After hours
$18.72▲ +0.00%
Oct 27, 4:31 PM ET
Volume 6.07M
Avg Volume (10D) 8.87M
Key Metrics & Fundamentals
Market Cap
$21.50B
P/E Ratio
–
Div Yield
2.62%
52W Range
9.92 - 18.83
% vs 50 MA
8.31%
% vs 200 MA
18.43%
RSI-14
62.3
MACD Histogram
+0.0300
Beta (1Y vs SPY)
0.69
Free Cash Flow
$322.00M
Gross Rev
$3.76B
Gross Profit
$1.46B
EBITDA
$796.40M
COGS
$2.30B
Operating Exp
$1.38B
Operating Income
$73.70M
EBIT
$73.70M
Pretax Income
-$64.00M
Net Income
-$118.80M
EPS (Diluted)
-0.10
Price & Volume History
Loading chart…
Recent News
Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?
Zacks · Oct 27, 2026 11:10 AM ET
Earnings Preview: What to Expect From Viatris' Report
Barchart · Oct 27, 2026 6:21 AM ET
IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave
Stocktwits · Oct 27, 2026 3:14 AM ET
Piper Sandler Adjusts Price Target on Viatris to $14 From $13
MT Newswires · Oct 26, 2026 6:03 AM ET
Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval
MarketBeat · Oct 25, 2026 8:02 AM ET
Pacira BioSciences (PCRX) Stock Gets Fair Value Boost After Viatris Deal Framing
Simply Wall St. · Oct 23, 2026 12:13 PM ET
A Look Back at Generic Pharmaceuticals Stocks’ Q2 Earnings: Viatris (NASDAQ:VTRS) Vs The Rest Of The Pack
StockStory · Oct 21, 2026 3:10 PM ET
JPMorgan Adjusts Viatris Price Target to $20 From $18
MT Newswires · Oct 21, 2026 9:24 AM ET
Viatris’ Dividend Has Room to Grow, but Will Management Deliver?
Insider Monkey · Oct 19, 2026 10:17 AM ET
Viatris Gets FDA Approval for Ryzumvi in the Treatment of Presbyopia
MT Newswires · Oct 16, 2026 4:31 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See VTRS's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.